Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.3%. BMY has a PE ratio of 53.4. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1...
Also read: Kraft Heinz and Unilever’s food fight